Dominari (DOMH) Projected to Post Quarterly Earnings on Wednesday

Dominari (NASDAQ:DOMH) is anticipated to issue its resultson Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $30.0760 million for the quarter.

Dominari Stock Performance

Shares of NASDAQ:DOMH opened at $3.39 on Wednesday. The company has a 50-day simple moving average of $3.00 and a 200-day simple moving average of $3.96. Dominari has a one year low of $2.68 and a one year high of $8.40. The stock has a market capitalization of $76.65 million, a price-to-earnings ratio of -0.87 and a beta of 0.69.

Dominari Dividend Announcement

The firm also recently announced a special dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be issued a $0.31 dividend. The ex-dividend date of this dividend is Friday, May 15th.

Institutional Investors Weigh In On Dominari

Institutional investors have recently made changes to their positions in the stock. Creek Drive Management Group LLC purchased a new stake in shares of Dominari during the 4th quarter worth $1,861,000. NewEdge Advisors LLC purchased a new position in shares of Dominari in the 4th quarter valued at about $50,000. Oxford Asset Management LLP purchased a new position in shares of Dominari in the 4th quarter valued at about $120,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Dominari in the 4th quarter valued at about $96,000. Finally, Susquehanna Advisors Group Inc. purchased a new position in shares of Dominari in the 4th quarter valued at about $182,000. 42.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DOMH has been the subject of a number of research reports. Wall Street Zen cut shares of Dominari from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Weiss Ratings cut shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, January 12th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Dominari currently has a consensus rating of “Sell”.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.